- Headquarters
- Hangzhou
- Founded
- 2017
- Business Model
- B2B
- Website
- qihanbio.com
- Total Funding
- $90.8M
- Last Round
- $16.0M Venture RoundSep 2023
- Rounds
- 3
About
Genome editing biotechnology company with world-leading capabilities in multiplexable genome editing, co-founded in 2017 by pioneers in the field.
Summary
Qihan Biotech is a Biotech company based in Hangzhou, China, founded in 2017. It has raised $90.8M in total across 3 rounds, most recently a $16.0M Venture Round round in Sep 2023. Investors include Zhejiang Industrial Fund Co., Ltd., LAV (Lilly Asia Ventures) and Sequoia Capital.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...